Replies to post #976 on Dendreon Corp fka DNDNQ

[ocyanblue]

Any trial where overall survival is the primary endpoint is a counter to Ocyan’s argument.

Well, ok. You seem a bit worked up and perhaps not thinking straight due to that. Let's try again. What did you think was my argument?

[i760]

You have failed to respond to the question.

You have argued in many posts that the p value needs to be allocated between TTP (a surrogate test) and survival (ultimate test).

Others (Clark & Ocyan) have argued that there is no need for allocation between a surrogate and the ultimate test.

So I ask you again for an example in which the FDA allocated p value between a surrogate test and the ultimate test, like a trial in which p value threshold for survival is reduced because there was an earlier surrogate test (like TTP).

Should you fail to provide an example, I can't help wonder if your view on this topic is just another example of hot air.